Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA appro...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Future Oncol
Autors principals: Zimmer, Alexandra S, Steinberg, Seth M, Smart, Dee Dee, Gilbert, Mark R, Armstrong, Terri S, Burton, Eric, Houston, Nicole, Biassou, Nadia, Gril, Brunilde, Brastianos, Priscilla K, Carter, Scott, Lyden, David, Lipkowitz, Stanley, Steeg, Patricia S
Format: Artigo
Idioma:Inglês
Publicat: Future Medicine Ltd 2020
Matèries:
Clinical Trial Protocol
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270957/
https://ncbi.nlm.nih.gov/pubmed/32270710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0094
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars